New Preclinical Study Finds Niagen® Corrects Social Deficits in Mouse Model of AutismBusiness Wire • 07/16/20
ChromaDex External Research Program (CERP™) Achieves 200th Material Transfer Agreement for Niagen® (Nicotinamide Riboside) ResearchBusiness Wire • 07/14/20
ChromaDex Announces New Study Results Highlighting Promising Anti-Viral Effects of Niagen® in Coronavirus Cell ModelBusiness Wire • 07/09/20
ChromaDex and the NIH-NIAID Rocky Mountain Laboratories Announce Study to Assess the Therapeutic Potential of Niagen® in COVID-19 Animal ModelsBusiness Wire • 07/07/20
New Preclinical Findings Suggest Boosting NAD+ with Niagen® Holds Potential for Slowing Aging Process and Reducing Metabolic DamageBusiness Wire • 06/30/20
ChromaDex Corporation's (CDXC) CEO Rob Fried on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/12/20
ChromaDex Corrects Statements Made by an Unaffiliated Third Party Regarding its Product and COVID-19GlobeNewsWire • 03/12/20
ChromaDex Corp. (CDXC) CEO Rob Fried on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/11/20
New Niagen® Nicotinamide Riboside (NR) Study Deepens Understanding of NAD Decline and Hearing Loss in Animal ModelGlobeNewsWire • 02/27/20
ChromaDex Partners with Personalized Nutrition Company, Persona Nutrition, Expanding Global Partnership with Nestlé Health ScienceGlobeNewsWire • 02/12/20
ChromaDex Launches New Line of High Purity Cannabinoid (CBD) Reference Standards Available for Research and Analytical Testing WorldwideGlobeNewsWire • 02/03/20
ChromaDex Achieves New Regulatory Milestones in the European Union & AustraliaGlobeNewsWire • 01/15/20
First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with HypertensionGlobeNewsWire • 01/06/20
ChromaDex Wins Nutritional Outlook’s 2019 “Best of Industry” Ingredient Supplier Award for Niagen®GlobeNewsWire • 12/16/19
ChromaDex Launches Tru Niagen® Pro 500, the Largest Serving of Patented Nicotinamide Riboside Available WorldwideGlobeNewsWire • 12/11/19
ChromaDex and Matakana Announce Expanded Retail Partnership in Australia & New ZealandGlobeNewsWire • 12/05/19
ChromaDex Receives Approval for Nicotinamide Riboside Chloride as an Ingredient for Complementary Medicines from the Australian Therapeutic Goods Administration (TGA)GlobeNewsWire • 12/02/19
European Commission Votes in Favor on Nicotinamide Riboside Chloride as a Novel FoodGlobeNewsWire • 11/20/19
ChromaDex Corporation's (CDXC) CEO Rob Fried on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/13/19
Tru Niagen® Wins ‘Most Favourite Brand’ Award Among Watsons Hong Kong Loyalty MembersGlobeNewsWire • 10/31/19
ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/30/19
New Study Demonstrates a Unique Role of Nicotinamide Riboside Over Other NAD PrecursorsGlobeNewsWire • 10/17/19
ChromaDex Statement Regarding the October 9th Order in the Central District of California LitigationGlobeNewsWire • 10/11/19